Megan S. Bacabac
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Megan S. Bacabac has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
- Wei Xu
McArdle Laboratory for Cancer Research University of Wisconsin–Madison Madison Wisconsin USA
12 shared publications - Aussie Suzuki
McArdle Laboratory for Cancer Research, Department of Oncology, University of Wisconsin-Madison, Madison, USA
11 shared publications - Christopher J. Fry
Cell Signaling Technology, Danvers, MA 01923, USA
11 shared publications - Eui-Jun Kim
University of Wisconsin–Madison 1 McArdle Laboratory for Cancer Research Madison, Wisconsin
11 shared publications - Jingjing Zhou
University of Wisconsin–Madison 1 McArdle Laboratory for Cancer Research Madison, Wisconsin
11 shared publications - Jordan R. Hoffman
Cell Signaling Technology, Danvers, Massachusetts
11 shared publications
Latest Publications
- Open Access
- 15 August 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 3 from CARM1-Mediated MAP2K4 Methylation Potentiates the Oncogenic Functions of MAP2K4 and Constitutes a Targetable Dependency in Triple-Negative Breast Cancer
Reverse expression patterns of CARM1 and MAP2K4 in breast cancer subtypes and CARM1-mediated MAP2K4 methylation potentiates the downstream JNK activation
- 15 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 3 from CARM1-Mediated MAP2K4 Methylation Potentiates the Oncogenic Functions of MAP2K4 and Constitutes a Targetable Dependency in Triple-Negative Breast Cancer
Reverse expression patterns of CARM1 and MAP2K4 in breast cancer subtypes and CARM1-mediated MAP2K4 methylation potentiates the downstream JNK activation
- Open Access
- 15 August 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 1 from CARM1-Mediated MAP2K4 Methylation Potentiates the Oncogenic Functions of MAP2K4 and Constitutes a Targetable Dependency in Triple-Negative Breast Cancer
Raw RPPA data, related to Figure 1
- 15 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 1 from CARM1-Mediated MAP2K4 Methylation Potentiates the Oncogenic Functions of MAP2K4 and Constitutes a Targetable Dependency in Triple-Negative Breast Cancer
Raw RPPA data, related to Figure 1
- Open Access
- 15 August 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 4 from CARM1-Mediated MAP2K4 Methylation Potentiates the Oncogenic Functions of MAP2K4 and Constitutes a Targetable Dependency in Triple-Negative Breast Cancer
Methylation of MAP2K4 promotes MDA-MB-468 cell proliferation and migration
- 15 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 4 from CARM1-Mediated MAP2K4 Methylation Potentiates the Oncogenic Functions of MAP2K4 and Constitutes a Targetable Dependency in Triple-Negative Breast Cancer
Methylation of MAP2K4 promotes MDA-MB-468 cell proliferation and migration
- Open Access
- 15 August 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 5 from CARM1-Mediated MAP2K4 Methylation Potentiates the Oncogenic Functions of MAP2K4 and Constitutes a Targetable Dependency in Triple-Negative Breast Cancer
CARM1i and PI3Ki elicited a synergistic anti-growth effect MDA-MB-231, SUM159 and Cal-51 TNBC cell lines
- 15 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 5 from CARM1-Mediated MAP2K4 Methylation Potentiates the Oncogenic Functions of MAP2K4 and Constitutes a Targetable Dependency in Triple-Negative Breast Cancer
CARM1i and PI3Ki elicited a synergistic anti-growth effect MDA-MB-231, SUM159 and Cal-51 TNBC cell lines
- Open Access
- 15 August 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 2 from CARM1-Mediated MAP2K4 Methylation Potentiates the Oncogenic Functions of MAP2K4 and Constitutes a Targetable Dependency in Triple-Negative Breast Cancer
Subcellular localization of CARM1, total MAP2K4 and me-MAP2K4 in MDA-MB-231 and Cal-51 parental cells and the corresponding CARM1KO cells.
- 15 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 2 from CARM1-Mediated MAP2K4 Methylation Potentiates the Oncogenic Functions of MAP2K4 and Constitutes a Targetable Dependency in Triple-Negative Breast Cancer
Subcellular localization of CARM1, total MAP2K4 and me-MAP2K4 in MDA-MB-231 and Cal-51 parental cells and the corresponding CARM1KO cells.
- Open Access
- 15 August 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 1 from CARM1-Mediated MAP2K4 Methylation Potentiates the Oncogenic Functions of MAP2K4 and Constitutes a Targetable Dependency in Triple-Negative Breast Cancer
Treatment with EZM2302 increases CARM1 and PRMT1 levels, and the list of proteins affected by BKM120, TP-064, or both, and the basal AKT activation status in various breast cancer cell lines.
- 15 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 1 from CARM1-Mediated MAP2K4 Methylation Potentiates the Oncogenic Functions of MAP2K4 and Constitutes a Targetable Dependency in Triple-Negative Breast Cancer
Treatment with EZM2302 increases CARM1 and PRMT1 levels, and the list of proteins affected by BKM120, TP-064, or both, and the basal AKT activation status in various breast cancer cell lines.
- Open Access
- 15 August 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 2 from CARM1-Mediated MAP2K4 Methylation Potentiates the Oncogenic Functions of MAP2K4 and Constitutes a Targetable Dependency in Triple-Negative Breast Cancer
The list of proteins whose levels are affected by treatment with TP-064, BKM120, or both in Fig. 1B.
- 15 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 2 from CARM1-Mediated MAP2K4 Methylation Potentiates the Oncogenic Functions of MAP2K4 and Constitutes a Targetable Dependency in Triple-Negative Breast Cancer
The list of proteins whose levels are affected by treatment with TP-064, BKM120, or both in Fig. 1B.
- Open Access
- 15 August 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 6 from CARM1-Mediated MAP2K4 Methylation Potentiates the Oncogenic Functions of MAP2K4 and Constitutes a Targetable Dependency in Triple-Negative Breast Cancer
CARM1i and PI3Ki synergistically inhibit the growth of a patient-derived xenograft organoid (PDxO)
- 15 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 6 from CARM1-Mediated MAP2K4 Methylation Potentiates the Oncogenic Functions of MAP2K4 and Constitutes a Targetable Dependency in Triple-Negative Breast Cancer
CARM1i and PI3Ki synergistically inhibit the growth of a patient-derived xenograft organoid (PDxO)
- Open Access
- 15 August 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 7 from CARM1-Mediated MAP2K4 Methylation Potentiates the Oncogenic Functions of MAP2K4 and Constitutes a Targetable Dependency in Triple-Negative Breast Cancer
PI3Ki and CARM1i combinational treatment strongly inhibited the growth of PDXs and 4T1 tumors in vivoorganoid (PDxO)
- 15 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 7 from CARM1-Mediated MAP2K4 Methylation Potentiates the Oncogenic Functions of MAP2K4 and Constitutes a Targetable Dependency in Triple-Negative Breast Cancer
PI3Ki and CARM1i combinational treatment strongly inhibited the growth of PDXs and 4T1 tumors in vivoorganoid (PDxO)
- Open Access
- 15 August 2025
- Published by American Association for Cancer Research (AACR)
Data from CARM1-Mediated MAP2K4 Methylation Potentiates the Oncogenic Functions of MAP2K4 and Constitutes a Targetable Dependency in Triple-Negative Breast Cancer
The arginine methyltransferase coactivator-associated arginine methyltransferase 1 (CARM1) is amplified/overexpressed in a variety of cancers, including triple-negative breast cancer (TNBC), spurring the interest of developing CARM1 inhibitors (CARM1i). In this study, we discovered that CARM1i treatment leads to elevated CARM1 levels as well as activation of AKT, which could result in long-term treatment resistance in breast cancer cells. CARM1 methylated MAP2K4 at arginine 58 in TNBC, and methylated-MAP2K4 localized to the nucleus and potentiated the proliferation- and metastasis-promoting functions of MAP2K4 via activation of JNK signaling. Inhibition of MAP2K4 by CARM1i led to AKT activation, which was abrogated by treatment with a PI3K inhibitor. Combining CARM1i and PI3K inhibitor elicited synergistic anticancer effects in TNBC cell lines, organoids, and patient-derived xenografts. This study demonstrates that, through inhibiting MAP2K4 methylation, CARM1i abrogates the feedback loop of MAP2K4 and PI3K signaling, supporting treatment with CARM1i as a therapeutic approach to improve the sensitivity of TNBC to PI3Ki.Significance:CARM1 mediates MAP2K4 activation and cross-talk with PI3K/AKT signaling, providing potential combination approaches for treating triple-negative breast cancer and explains the paradoxical role of MAP2K4 in ER+ and triple-negative breast cancer.
- 15 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessData from CARM1-Mediated MAP2K4 Methylation Potentiates the Oncogenic Functions of MAP2K4 and Constitutes a Targetable Dependency in Triple-Negative Breast Cancer
The arginine methyltransferase coactivator-associated arginine methyltransferase 1 (CARM1) is amplified/overexpressed in a variety of cancers, including triple-negative breast cancer (TNBC), spurring the interest of developing CARM1 inhibitors (CARM1i). In this study, we discovered that CARM1i treatment leads to elevated CARM1 levels as well as activation of AKT, which could result in long-term treatment resistance in breast cancer cells. CARM1 methylated MAP2K4 at arginine 58 in TNBC, and methylated-MAP2K4 localized to the nucleus and potentiated the proliferation- and metastasis-promoting functions of MAP2K4 via activation of JNK signaling. Inhibition of MAP2K4 by CARM1i led to AKT activation, which was abrogated by treatment with a PI3K inhibitor. Combining CARM1i and PI3K inhibitor elicited synergistic anticancer effects in TNBC cell lines, organoids, and patient-derived xenografts. This study demonstrates that, through inhibiting MAP2K4 methylation, CARM1i abrogates the feedback loop of MAP2K4 and PI3K signaling, supporting treatment with CARM1i as a therapeutic approach to improve the sensitivity of TNBC to PI3Ki.Significance:CARM1 mediates MAP2K4 activation and cross-talk with PI3K/AKT signaling, providing potential combination approaches for treating triple-negative breast cancer and explains the paradoxical role of MAP2K4 in ER+ and triple-negative breast cancer.